Terns Pharmaceuticals Files Q1 2025 10-Q
Ticker: TERN · Form: 10-Q · Filed: May 8, 2025 · CIK: 1831363
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
**TERNS Q1 2025 10-Q FILED: Financials and agreements updated. Check for details.**
AI Summary
Terns Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including retained earnings and fair value measurements. It also references various agreements and plans, such as the Hansoh Option and License Agreement and the Two Thousand And Seventeen Incentive Award Plan.
Why It Matters
This filing provides investors with an update on Terns Pharmaceuticals' financial health and operational details for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Terns is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial reporting quarter.)
- 20250508 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- 20250508 (date) — Filing date
- Hansoh Option and License Agreement (agreement) — Referenced agreement
- Two Thousand And Seventeen Incentive Award Plan (plan) — Referenced employee plan
FAQ
What were Terns Pharmaceuticals' retained earnings as of March 31, 2025?
The filing indicates retained earnings as of March 31, 2025, but the specific dollar amount is not provided in this header data.
What is the business address of Terns Pharmaceuticals?
The business address is 1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY, CA 94404.
When was the Two Thousand And Seventeen Incentive Award Plan established?
The plan was established between February 1, 2021, and February 28, 2021.
What is the SIC code for Terns Pharmaceuticals?
The Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
Does the filing mention any specific expenses related to Terns' operations?
Yes, the filing references 'TERNSixZeroOneRelatedExpenses' for the period of January 1, 2024, to March 31, 2024.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Terns Pharmaceuticals, Inc. (TERN).